Transfer

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma

Authors: Llovet JM, Ducreux M, Lencioni R, Di Bisceglie AM, Galle PR, Dufour JF, Greten TF, Raymond E, Roskams T, De Baere T, Ducreux M, Mazzaferro V, Bernardi M.

Reference: J Hepatol. 2012 Jun;56(6):1430
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

Authors: Galle PR, Forner A, Llovet JM, Mazzaferro V, Piscaglia F, Raoul JL, Schirmacher P, Vilgrain V

Reference: J Hepatol. 2018 Jul;69(1):182-23
Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Authors: Vogel A, Cervantes A, Chau I, Daniele B, Llovet J, Meyer T, Nault JC, Neumann U, Ricke J, Sangro B, Schirmacher P, Verslype C, Zech CJ, Arnold D, Martinelli E; ESMO Guidelines Committee

Reference: Ann Oncol. 2018 Oct 1;29(Suppl 4):iv238-iv255
Design and endpoints of clinical trials in hepatocellular carcinoma

Authors: Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J, Gores GJ; Panel of Experts in HCC-Design Clinical Trials

Reference: J Natl Cancer Inst. 2008 May 21;100(10):698-711

Patent